Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this ...

Immunoglobulin A (IgA) nephropathy, also called Berger’s disease, is an autoimmune disease that affects your kidneys. IgA is an antibody. Antibodies are proteins made by your immune system.

IgA nephropathy is progressive. That means it gets worse the longer you have it. It's not curable, but treatments can slow kidney damage and keep these organs working longer. It's important to ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...